Matches in Nanopublications for { <http://www.nextprot.org/nanopubs#NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E._1> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E._1 type RangedSequencePosition NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E.assertion.
- NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E._1 type SO_0001148 NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E.assertion.
- NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E._1 comment "Some reduction in transactivation but, completely abolishes MAPK9-mediated activation. Abolishes MAPK9-mediated and greatly reduces adenovirus E1A-mediated transactivation; when associated with A-51 and A-53. Abolishes adenovirus 2 E1A-mediated transactivation; when associated with A-14; A-51 and A-53." NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E.assertion.
- NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E._1 SIO_000053 NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E._2 NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E.assertion.
- NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E._1 SIO_000053 NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E._3 NX_P17544-2_MUTAGEN_101_101.RA4YC4U5D_qSoguH3jpTM1HHPI6uzv31WAdQxVTcU8u-E.assertion.